semaglutide side effects vision loss eye rot Pharmaceutical giant Novo Nordisk is facing mounting legal pressure as more than 1,800 As critical as it is

When taken concurrently, these effects may be more pronounced or uncomfortable, potentially affecting your adherence to treatment and overall wellbeing

All of the claims raise similar allegations that the drug makers knew or should have known that their drugs put users at increased risk of potentially life-threatening gastrointestinal side effects, such as gastroparesis (stomach paralysis), ileus and intestinal obstruction

Meaningful weight loss and improvement in conditions like type 2 diabetes, sleep apnea and high blood pressure More energy for work, family and movement Long-term support for weight maintenance when paired with healthy habits Within weeks, many people need fewer medications, sleep better and move with less pain, says Dr

For instance, In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions